Table 1 Duration of treatment and cumulative MR rates by 60 months.

From: Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

 

Bosutinib

Imatinib

 

Duration of treatment, mo

n = 268

n = 265

 

 Median (range)

55.1 (0.3–60.1)

55.0 (0.7–56.8)

 

Cumulative response rates, % (95% CI)

n = 268

n = 268

ORa (95% CI)

 MMR

73.9 (68.6–79.1)

64.6 (58.8–70.3)

1.57 (1.08–2.28)

 MR4

58.2 (52.3–64.1)

48.1 (42.2–54.1)

1.50 (1.07–2.12)

 MR4.5

47.4 (41.4–53.4)

36.6 (30.8–42.3)

1.57 (1.11–2.22)

Cumulative molecular response rates by Sokal risk group at screening, % (95% CI)

 Low risk

n = 95

n = 106

ORa (95% CI)

  MMR

75.8 (67.2–84.4)

72.6 (64.2–81.1)

1.18 (0.63–2.22)

  MR4

60.0 (50.1–69.9)

55.7 (46.2–65.1)

1.20 (0.68–2.10)

  MR4.5

53.7 (43.7–63.7)

42.5 (33.0–51.9)

1.57 (0.90–2.74)

 Intermediate risk

n = 117

n = 105

 

  MMR

74.4 (66.4–82.3)

63.8 (54.6–73.0)

1.65 (0.93–2.92)

  MR4

56.4 (47.4–65.4)

46.7 (37.1–56.2)

1.48 (0.87–2.51)

  MR4.5

42.7 (33.8–51.7)

37.1 (27.9–46.4)

1.26 (0.74–2.17)

 High risk

n = 56

n = 57

 

  MMR

69.6 (57.6–81.7)

50.9 (37.9–63.9)

2.22 (1.03–4.79)

  MR4

58.9 (46.0–71.8)

36.8 (24.3–49.4)

2.46 (1.15–5.24)

  MR4.5

46.4 (33.4–59.5)

24.6 (13.4–35.7)

2.66 (1.20–5.92)

  1. All ratios are bosutinib vs. imatinib. OR > 1 favor bosutinib.
  2. CI confidence interval, MMR major molecular response, MR molecular response, OR odds ratio.
  3. aOverall adjusted for Sokal risk group and region as determined at the time of randomization and unadjusted for subgroups.
Back to article page